Key Points
- Director Srinivas Akkaraju bought 38,702 shares on Nov. 28 at $7.64 each ( ~$295,683) and has been buying aggressively — roughly 816,849 shares across November–December — with filings showing he directly owned about 730,499 shares valued at ~$5.58M.
- Alumis stock is down 4.2% (opened $7.35) and the company reported a miss with Q3 EPS of −$1.06 and revenue of $2.07M vs. $3.14M expected; analysts’ consensus is a “Moderate Buy” with an average target of $19.20.
Alumis Inc. (NASDAQ:ALMS - Get Free Report) Director Srinivas Akkaraju acquired 38,702 shares of the stock in a transaction dated Friday, November 28th. The stock was acquired at an average cost of $7.64 per share, for a total transaction of $295,683.28. Following the purchase, the director directly owned 730,499 shares in the company, valued at approximately $5,581,012.36. The trade was a 5.59% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Srinivas Akkaraju also recently made the following trade(s):
- On Monday, December 1st, Srinivas Akkaraju bought 86,350 shares of Alumis stock. The shares were acquired at an average cost of $7.46 per share, with a total value of $644,171.00.
- On Wednesday, November 26th, Srinivas Akkaraju bought 48,537 shares of Alumis stock. The shares were acquired at an average price of $7.64 per share, with a total value of $370,822.68.
- On Thursday, November 20th, Srinivas Akkaraju purchased 125,743 shares of Alumis stock. The stock was acquired at an average price of $7.20 per share, for a total transaction of $905,349.60.
- On Wednesday, November 19th, Srinivas Akkaraju acquired 137,772 shares of Alumis stock. The shares were bought at an average price of $6.56 per share, with a total value of $903,784.32.
- On Tuesday, November 18th, Srinivas Akkaraju acquired 102,652 shares of Alumis stock. The shares were bought at an average cost of $6.05 per share, with a total value of $621,044.60.
- On Monday, November 17th, Srinivas Akkaraju bought 914 shares of Alumis stock. The stock was bought at an average price of $5.51 per share, for a total transaction of $5,036.14.
- On Thursday, November 13th, Srinivas Akkaraju bought 276,179 shares of Alumis stock. The shares were bought at an average cost of $5.25 per share, for a total transaction of $1,449,939.75.
Alumis Stock Down 4.2%
NASDAQ:ALMS opened at $7.35 on Tuesday. Alumis Inc. has a 1-year low of $2.76 and a 1-year high of $10.49. The firm has a market capitalization of $767.27 million, a price-to-earnings ratio of -1.81 and a beta of -1.91. The stock has a fifty day simple moving average of $5.11 and a 200 day simple moving average of $4.37.
Alumis (NASDAQ:ALMS - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The business had revenue of $2.07 million during the quarter, compared to analysts' expectations of $3.14 million. Equities analysts predict that Alumis Inc. will post -8.51 earnings per share for the current year.
Wall Street Analyst Weigh In
ALMS has been the subject of several research analyst reports. HC Wainwright restated a "buy" rating and issued a $14.00 price target on shares of Alumis in a research report on Thursday, August 14th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Alumis in a research report on Tuesday, November 25th. Morgan Stanley lowered their price target on Alumis from $23.00 to $22.00 and set an "overweight" rating on the stock in a report on Friday, August 15th. Finally, Wall Street Zen downgraded Alumis from a "hold" rating to a "sell" rating in a research note on Saturday, November 15th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Alumis currently has an average rating of "Moderate Buy" and an average target price of $19.20.
Check Out Our Latest Report on ALMS
Hedge Funds Weigh In On Alumis
Several institutional investors and hedge funds have recently modified their holdings of the stock. Orbimed Advisors LLC acquired a new position in shares of Alumis in the second quarter worth $5,779,000. Velan Capital Investment Management LP purchased a new position in Alumis in the second quarter valued at about $4,863,000. Woodline Partners LP increased its position in Alumis by 809.7% in the 3rd quarter. Woodline Partners LP now owns 1,751,150 shares of the company's stock worth $6,987,000 after purchasing an additional 1,558,660 shares during the last quarter. Samsara Biocapital LLC increased its position in Alumis by 47.0% in the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company's stock worth $14,404,000 after purchasing an additional 1,534,872 shares during the last quarter. Finally, Tybourne Capital Management HK Ltd. purchased a new stake in shares of Alumis during the 2nd quarter worth about $4,198,000.
About Alumis
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
